
Kala Pharmaceuticals Revenue | KALA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 3.89 M | 11.2 M | 6.36 M | 6.07 M | - | - | - | 45 K | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.2 M | 45 K | 5.52 M |
Quarterly Revenue Kala Pharmaceuticals
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 420 K | 2.1 M | 1.37 M | - | 3.07 M | 3.05 M | 3.27 M | 2.24 M | 2.22 M | 833 K | 1.07 M | 1.18 M | 1.45 M | 2.06 M | 1.39 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.27 M | 420 K | 1.84 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
PainReform Ltd.
PRFX
|
17 K | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
35 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
814 K | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
9.85 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
18.9 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
184 M | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
567 K | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
9.75 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
18.8 M | - | -23.43 % | $ 495 K | ||
|
BioXcel Therapeutics
BTAI
|
642 K | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
23.7 M | - | -24.84 % | $ 2.64 M | ||
|
NeuBase Therapeutics
NBSE
|
-416 K | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
37.4 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | ||
|
Nabriva Therapeutics plc
NBRV
|
36.9 M | - | - | $ 4.55 M | ||
|
scPharmaceuticals
SCPH
|
36.3 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
7 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
5.32 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
195 M | - | - | $ 4.62 B | ||
|
NanoString Technologies
NSTG
|
127 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
2.51 M | - | -81.12 % | $ 4.28 M | ||
|
Sorrento Therapeutics
SRNE
|
62.8 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
30 M | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
300 K | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
601 K | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
5 K | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
82 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
2.01 M | $ 0.93 | -4.11 % | $ 10.5 M | ||
|
Fortress Biotech
FBIO
|
63.3 M | $ 1.89 | 6.78 % | $ 52.7 M | ||
|
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | ||
|
Longeveron
LGVN
|
1.2 M | $ 1.65 | -9.34 % | $ 29 B | ||
|
Ampio Pharmaceuticals
AMPE
|
469 K | - | -11.43 % | $ 502 K | ||
|
Mersana Therapeutics
MRSN
|
40.5 M | - | - | $ 3.56 B | ||
|
Akari Therapeutics, Plc
AKTX
|
368 K | $ 6.83 | 1.71 % | $ 460 B | ||
|
MediWound Ltd.
MDWD
|
21.8 M | $ 13.59 | 0.33 % | $ 370 M | ||
|
CymaBay Therapeutics
CBAY
|
31.1 M | - | - | $ 3.45 B | ||
|
Keros Therapeutics
KROS
|
244 M | $ 11.04 | -3.07 % | $ 411 M | ||
|
Kazia Therapeutics Limited
KZIA
|
42 K | $ 4.9 | -8.75 % | $ 75.9 M |